about
Microwave coagulation for liver metastasesTransarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastasesMicrowave coagulation for liver metastasesTransarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastasesPostoperative adjuvant transarterial (chemo)embolisation after liver resection for hepatocellular carcinomaCryotherapy for liver metastasesTransarterial (chemo)embolisation versus other nonsurgical ablation methods for liver metastasesElectro-coagulation for liver metastasesPercutaneous ethanol injection for liver metastasesTransarterial (chemo)embolisation for liver metastasesElectro-coagulation for liver metastasesPercutaneous ethanol injection for liver metastasesCryotherapy for liver metastasesExtragastric manifestations of Helicobacter pylori infection: Possible role of bacterium in liver and pancreas diseasesGene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignanciesDownregulation of Kinesin spindle protein inhibits proliferation, induces apoptosis and increases chemosensitivity in hepatocellular carcinoma cells.Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.Adenovirus-delivered CIAPIN1 small interfering RNA inhibits HCC growth in vitro and in vivoEfficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis.Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma.Spontaneous ruptured hepatocellular carcinoma.Integrating subpathway analysis to identify candidate agents for hepatocellular carcinoma.General transcription factor IIb overexpression and a potential link to proliferation in human hepatocellular carcinoma.Gene therapy of liver tumors with human liver-specific nanoparticles.Bioreducible PEI-siRNA Nanocomplex for Liver Cancer Therapy: Transfection, Biodistribution, and Tumor Growth InhibitionIn Vivo
P2860
Q24197493-29C5FD43-9CF2-4A93-951D-2186AA62842EQ24197776-7EA5B502-90AF-43A1-AE34-9A1C54A104C1Q24199085-91A2DAD5-B405-44B8-BA28-D6BE1B0D65F8Q24200851-EE4A2DDD-0E48-4305-BB88-D102EFA983FFQ24202070-E01929C9-B1DC-4947-BBDB-B9D722E413F3Q24202266-71B5FD13-1B3D-4C69-B0F6-B7C297020502Q24202458-CE5102B6-9E4E-4118-A66B-71D2C3E2809CQ24202672-BC2796D7-06CE-4A41-95EE-ED5147F8C3C1Q24202714-774AD415-05F7-45CC-ABFC-5DCF4704404CQ24234878-7BA8669F-DC18-412B-B43D-028176A498FFQ24234987-FC6CD80D-7A29-4546-9E5F-939B6E3329ACQ24235855-4E83516A-BD01-4E0C-A238-D84F43049B4FQ24236389-39448A7F-EFA7-462D-BD2C-48E28BFFECB5Q26771145-D2B2CED1-8DA3-469D-A0F5-DD57062551A8Q34482357-C39857B5-664F-431B-A211-463C9C3F6EE6Q35065391-102471D5-3808-466D-816A-179891BA6A0EQ35567765-F821AA37-6856-42D1-8D15-B79E5ED3E7D5Q36747526-E6496E38-3FA7-48FE-8B1A-2CFC33F481B4Q36838024-740C25EF-63A7-4ABE-8740-65E512422FD3Q37718809-6DAB8CC3-29BA-45F5-A961-EC49CDB61B55Q38309560-D6A63740-0847-4FBD-BAC0-EDBE0C74BB87Q38335991-AC0E6AE6-7F10-49E3-95B4-D0F1557E4FE2Q38944703-09A80784-FC4F-4EA1-9A87-AB02C023A819Q39261898-63BEAE11-9EC9-4EC4-9577-AF8A14BF003FQ40228742-6BA189F3-3501-4339-A1DD-21FEFB9D8507Q59018169-A4EF382F-7CB9-4B17-BA15-9708F8A6F906
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Primary liver tumors.
@ast
Primary liver tumors.
@en
Primary liver tumors.
@nl
type
label
Primary liver tumors.
@ast
Primary liver tumors.
@en
Primary liver tumors.
@nl
prefLabel
Primary liver tumors.
@ast
Primary liver tumors.
@en
Primary liver tumors.
@nl
P2860
P1476
Primary liver tumors.
@en
P2093
P2860
P304
P356
10.1002/1098-2388(200009)19:2<135::AID-SSU6>3.0.CO;2-A
P577
2000-09-01T00:00:00Z